Onychomysosis
☆ Na nsonaazụ Stiftung Warentest nke 2022 sitere na Germany, afọ ojuju ndị ahịa na ModelDerm dị ntakịrị ntakịrị karịa na nyocha telemedicine akwụ ụgwọ.
mbọ ụkwụ Onychomysosis metụrụ ya aka
Ụkwụ mmadụ nwere ọrịa ntu fungal izu iri n'ime usoro ọgwụgwọ ọnụ nke terbinafine. Rịba ama eriri ntu ahụ dị mma n'azụ ntu nje ndị fọdụrụnụ.
References
Usoro ọgwụgwọ antifungal bụ ọgwụgwọ kachasị dị irè. Meta-analyses na-egosi ọnụego ọgwụgwọ mycotic dị ka ndị a: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48% . Ntu ntu na-ejikọta ọnụ na-abawanye ọnụ ọgụgụ ọgwụgwọ. Usoro ọgwụgwọ na ciclopirox adịghị arụ ọrụ nke ọma; ọ nwere ọnụego ọdịda karịrị 60%.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
Onychomycosis bụ ọrịa fungal nke na-emetụta mbọ. Mgbe dermatophytes kpatara ya, a na-akpọ ya tinea unguium. Onychomycosis gụnyere ọrịa nke dermatophytes, yiasts, na ebu kpatara. Nsogbu ntu nke ọrịa fungal na-akpata na-akpọ nail dystrophy. Ọ bụ ezie na ọ nwere ike imetụta ma mbọ aka na mbọ ụkwụ, onychomycosis na-akarịkarị. Edemede a na-atụle akụkụ dị iche iche nke mbọ ụkwụ onychomycosis, dị ka mmetụta ya, ụdị ụlọ ọgwụ, ọkwa, nyocha na ọgwụgwọ. Ọ bụ ezie na ọ bụghị ihe na-eyi ndụ egwu, onychomycosis nwere ike ịkpata nsogbu siri ike dị ka cellulitis, sepsis, ọrịa ọkpụkpụ, mmebi anụ ahụ, na ntu ntu.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
Terbinafine bụ ọgwụ na-alụ ọgụ maka ọrịa fungal site na igbochi squalene epoxidase. Ọ dị irè megide ọtụtụ ụdị fungi anụ ahụ ma kwado ya maka ọgwụgwọ ero ntu mgbe a na-e ya ọnụ. Ọ bụ ezie na ọtụtụ mmetụta ndị dị ka isi ọwụwa na ihe gbasara afọ dị obere ma na-apụ n'onwe ha, mgbanwe na uto (dysgeusia) nwere ike ịdịgasị iche site na nwayọọ ruo dị njọ, mgbe ụfọdụ na-eduga ná nkwụsị. Mgbanwe ụtọ na-adịgide adịgide dị ụkọ mana akọpụtala ya.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
Onychomycosis bụ ọrịa fungal nke na-emetụta mbọ. Ihe dị ka 90% nke ọrịa ntu na 75% nke ntu mkpịsị aka na-ebute fungi (Trichophyton mentagrophytes, Trichophyton rubrum) . Mgbaàmà na-agụnye agba ntu, ntu, ikewapụ n'àkwà ntu, na oke ibu. Ọgwụgwọ na-agụnyekarị ọgwụ ọnụ dị ka terbinafine ma ọ bụ itraconazole, yana ọgwụgwọ ndị dị n'elu bụ nhọrọ maka ikpe dị nro ma na-agafeghị oke.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.
Ọgwụ antifungal terbinafine nke a na-ewere n'ọnụ yiri ka ọ kacha dị irè mana terbinafine na-ejikọta ya na mmetụta dị n'akụkụ imeju.
Onychomysosis na-eme n'ihe dị ka pasent 10 nke ndị okenye, yana ndị agadi na-emetụtakarị. A na-emetụta ụmụ nwoke karịa ụmụ nwanyị. Onychomysosis na-anọchi anya ihe dị ka ọkara ọrịa ntu. Nke a pụtara na nrụrụ nke mbọ ụkwụ nwekwara ike isi na ihe kpatara ndị ọzọ karịa onychomycosis.
○ Ọgwụgwọ - Ọgwụ OTC
O siri ike ịgwọ onychomycosis na ọgwụ ndị dị n'akụkụ n'ihi na ọ na-esiri ọgwụ ike ịbanye n'ime mbọ ụkwụ gbajiri agbaze.
#Ketoconazole
#Clotrimazole
#Miconazole
#Terbinafine
#Butenafine [Lotrimin]
#Tolnaftate
○ Ọgwụgwọ
A na-achọkarị ọgwụgwọ ogologo oge ruo mgbe a na-ewepụ ntu ahụ nwere ọrịa kpamkpam.
#Terbinafine (oral)
#Itraconazole
#Efinaconazole lacquer [Jublia]
#Ciclopirox lacquer